Notably, many BCL-2 proteins are downstream factors of the RAS/BRAF/MAPK and PI3K/AKT signaling pathways, the activation of which contributes to the relapse of melanoma from treatment with targeted therapies [9]. The gene discussed is BRAF; the disease is melanoma.